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Introduction and objectives: In Crohn's disease (CD), there is a discrepancy between clinical activity of the disease 
(symptoms) and intestinal healing. However absence of tissue healing (CDEIS≥3$) is associated with the risk of relapse 
and tissue damage progression. Endoscopy is costly and invasive. Hence serum biomarkers correlating with intestinal 
healing could improve disease management. We aimed to identify potential biomarkers associated to CD mucosal 
healing by a shotgun proteomics label free study done on the STORI trial1 sera analysed at base line. 
Material and methods - Experimental design 
STORI1 clinical trial design 
$ CDEIS = Crohn Disease Endoscopic Index of Severity 
1Louis et al., Maintenance of Remission Among Patients with Crohn's on Anti-Metabolite Therapy after Infliximab Therapy is Stopped, in Gastroenterology, 2012 Jan;142(1):63-70.  
2 Y. Mohammed, et al , PeptidePicker: a Scientific Workflow with Web Interface for Selecting Appropriate Peptides for Targeted Proteomics Experiments, Journal of Proteomics,2014, Vol106, p151–161.  
3 NCRR, http://prowl.rockefeller.edu/prowl/pepfrag.html  
Results of differential analysis  
Protein Identification Parameters (PLGS algorithm):  
*Uniprot Human data base 
*3 fragment matches per peptide 
*7 fragment matches per protein 
*Minimum 2 peptides per protein 
*max 4% FDR at the protein level 
*Trypsin as digest reagent  
*Max 2 miss-cleavages allowed 
*Carbamidomethyl C as fixed modif. 
*Oxidation M, Phos STY, as variable modif. 
Differential analysis parameters: 
 
*Normalization: mean of all identified peptides 
*Ratio minimum: 1.5  
*Significant Anova P value only (≤0.05) 
*Frequence of observation: 80% of samples of all 
groups 
*  1 – Quantif. on peptides unique to 1 protein 
assigment (=« non conflictual peptides »). 
    2 – Quantif.on all peptides  
Differential analysis parameters: 
 
*Normalization: Gaussian all peptides  
*Ratio minimum: 1.5  
*Significant P value only (0 to 0.5 or 
0.95 to 1) 
*Frequence of observation:  
 4/6 R or 4/7 NR or all pool replicates 
for the mucosal healing question 
PLGS vs2.5: 
   R vs NR = 18 Proteins of Interest  
   CDEIS>3 vs CDEIS≤3 =  17 POI  
13 4 14* 
ProGenesis QI for Proteomics v1.0: 
CDEIS>3 vs 
 CDEIS ≤3 
R vs NR 
Patients information 
Aim: Evaluation of relapse duration when patient reach remission under infliximab and 
anti-metabolite treatments and following IFX treatment withdrawal.  
Results: For complete study, see Louis et al1.  
After a median 28 months follow-up, 50% of patients relapsed. Mucosal healing is 
monitored by endoscopy at base line and CDEIS evaluation (CDEIS ≤3: mucosal healing, 











R vs NR = 39 POI and  
22 POI ≈ distribution 
102 39* 28 





*C-Reactive Protein  
(hsCRP level) is associted  to 
relapse prediction, through a 
time dependent analysis 
together with leukocyte count, 
fecal calprotectin and HB 
levels1  
